Nothing Special   »   [go: up one dir, main page]

AU2003237076A1 - Therapeutical use of anti-cd70 antibody for treating or preventing aids - Google Patents

Therapeutical use of anti-cd70 antibody for treating or preventing aids

Info

Publication number
AU2003237076A1
AU2003237076A1 AU2003237076A AU2003237076A AU2003237076A1 AU 2003237076 A1 AU2003237076 A1 AU 2003237076A1 AU 2003237076 A AU2003237076 A AU 2003237076A AU 2003237076 A AU2003237076 A AU 2003237076A AU 2003237076 A1 AU2003237076 A1 AU 2003237076A1
Authority
AU
Australia
Prior art keywords
antibody
treating
therapeutical use
preventing aids
aids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003237076A
Inventor
Rene Antonius Wilhelmus Van Lier
Marinus Hendricus Jozef Van Oers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Sanquin Bloedvoorziening
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Publication of AU2003237076A1 publication Critical patent/AU2003237076A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003237076A 2003-05-23 2003-05-23 Therapeutical use of anti-cd70 antibody for treating or preventing aids Abandoned AU2003237076A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2003/000385 WO2004104045A1 (en) 2003-05-23 2003-05-23 Therapeutical use of anti-cd70 antibody for treating or preventing aids

Publications (1)

Publication Number Publication Date
AU2003237076A1 true AU2003237076A1 (en) 2004-12-13

Family

ID=33476091

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003237076A Abandoned AU2003237076A1 (en) 2003-05-23 2003-05-23 Therapeutical use of anti-cd70 antibody for treating or preventing aids

Country Status (2)

Country Link
AU (1) AU2003237076A1 (en)
WO (1) WO2004104045A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ES2457538T3 (en) 2003-02-20 2014-04-28 Seattle Genetics, Inc. Anti-CD70-drug antibody conjugates and their use for the treatment of cannula and immune disorders
AU2005295595C1 (en) 2004-10-15 2012-06-21 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
NZ566395A (en) * 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
WO2015032906A2 (en) 2013-09-05 2015-03-12 Bionovion Holding B.V. Cd70-binding peptides and method, process and use relating thereto
WO2022105914A1 (en) * 2020-11-23 2022-05-27 江苏先声药业有限公司 Antibody binding to cd70 and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L

Also Published As

Publication number Publication date
WO2004104045A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
AU2003224788A1 (en) Method for treatment of tissue
AU2004255187A1 (en) Device for treatment of human or animal barrier membranes
AU2003298043A1 (en) Surface treatment of medical device
AU2003249244A1 (en) Methods for the treatment of neoplasms
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002257936A1 (en) Methods of well treatment
DE60322451D1 (en) 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain
GB0329874D0 (en) Compounds useful for the treatment of diseases
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
AU2003260778A1 (en) Treatment of pipes
AU2003237076A1 (en) Therapeutical use of anti-cd70 antibody for treating or preventing aids
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
AU2003277728A1 (en) Apparatus for the biological treatment of wastewater
EP1691776A4 (en) Treatment of aids
AU2003221005A1 (en) Method of wastewater treatment
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2002249891A1 (en) Compounds and methods for the diagnosis and treatment of babesia infection
AU2002342715A1 (en) Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
AU2002951913A0 (en) Method of treatment
AU2003274359A1 (en) Treatment of fluids
AU2002343085A1 (en) Tnf-alpha inhibitors for the treatment of hepatic diseases
AU2003208809A1 (en) Treatment of neuroblastoma

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase